Drug Profile
Peginterferon alfa-2b biosimilar - Nanogen Biopharmaceutical
Alternative Names: Peg-Interferon alfa 2b - Nanogen Biopharmaceutical; PegstatLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B; Hepatitis C
Most Recent Events
- 25 Jul 2019 Launched for Hepatitis C in Vietnam before July 2019 (SC)
- 17 Mar 2016 Peginterferon alfa-2b biosimilar is still under preregistration for Hepatitis B and Hepatitis C in Vietnam (SC)
- 12 Mar 2014 Preregistration for Hepatitis B in Vietnam (SC)